When does quality-adjusting life-years matter in cost-effectiveness analysis?

被引:77
作者
Chapman, RH
Berger, M
Weinstein, MC
Weeks, JC
Goldie, S
Neumann, PJ
机构
[1] Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Program Econ Evaluat Med Technol, Boston, MA 02115 USA
[2] Merck & Co Inc, W Point, PA USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
关键词
quality-adjusted life-years; preference weights; utilities; cost-utility analysis; cost-effectiveness analysis;
D O I
10.1002/hec.853
中图分类号
F [经济];
学科分类号
02 ;
摘要
Purpose: This paper investigates the impact of quality-of-life adjustment on cost-effectiveness analyses, by comparing ratios from published studies that have reported both incremental costs per (unadjusted) life-year and per quality-adjusted life-year for the same intervention. Methods: A systematic literature search identified 228 original cost-utility analyses published prior to 1998. Sixty-three of these analyses (173 ratio pairs) reported both cost/LY and cost/QALY ratios for the same intervention, from which we calculated medians and means, the difference between ratios (cost/LY minus cost/ QALY) and between reciprocals of the ratios, and cost/LY as a percentage of the corresponding cost/QALY ratio. We also compared the ratios using rank-order correlation, and assessed the frequency with which quality-adjustment resulted in a ratio crossing the widely used cost-effectiveness thresholds of $20000, $50000, and $100000/QALY or LY. Results: The mean ratios were $69100/LY and $103100/QALY, with corresponding medians of $24600/LY and $20400/QALY. The mean difference between ratios was approximately -$34300 (median difference: $1300), with 60% of ratio pairs differing by $10000/year or less. Mean difference between reciprocals was 59 (QA)LYs per million dollars (median: 2.1). The Spearman rank-order correlation between ratio types was 0.86 (p<0.001). Quality-adjustment led to a ratio moving either above or below $50000/LY (or QALY) in 8% of ratio pairs, and across 100000 in 6% of cases. Conclusions: In a sizable fraction of cost utility analyses, quality adjusting did not substantially alter the estimated cost-effectiveness of an intervention, suggesting that sensitivity analyses using ad hoc adjustments or 'off-the-shelf' utility weights may be sufficient for many analyses. The collection of preference weight data should be subjected to the same scrutiny as other data inputs to cost-effectiveness analyses, and should only be undertaken if the value of this information is likely to be greater than the cost of obtaining it. Copyright (C) 2004 John Wiley Sons, Ltd.
引用
收藏
页码:429 / 436
页数:8
相关论文
共 15 条
[1]   A comprehensive league table of cost-utility ratios and a sub-table of "Panel-worthy" studies [J].
Chapman, RH ;
Stone, PW ;
Sandberg, EA ;
Bell, C ;
Neumann, PJ .
MEDICAL DECISION MAKING, 2000, 20 (04) :451-467
[2]   COST-EFFECTIVENESS ANALYSIS - A CONVERSATION WITH MY FATHER [J].
EDDY, DM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (12) :1669-&
[3]   Economic foundations of cost-effectiveness analysis [J].
Garber, AM ;
Phelps, CE .
JOURNAL OF HEALTH ECONOMICS, 1997, 16 (01) :1-31
[4]   COST-UTILITY IN PRACTICE - A POLICY MAKERS GUIDE TO THE STATE-OF-THE-ART [J].
GERARD, K .
HEALTH POLICY, 1992, 21 (03) :249-279
[5]  
Gold MR, 1996, COST EFFECTIVENESS H
[6]   Evaluating the cost-effectiveness of clinical and public health measures [J].
Graham, JD ;
Corso, PS ;
Morris, JM ;
Segui-Gomez, M ;
Weinstein, MC .
ANNUAL REVIEW OF PUBLIC HEALTH, 1998, 19 :125-152
[7]  
*HARV CTR RISK AN, CUA DAT BAS STAND ME
[8]   Willingness to pay for a quality-adjusted life year: In search of a standard [J].
Hirth, RA ;
Chernew, ME ;
Miller, E ;
Fendrick, AM ;
Weissert, WG .
MEDICAL DECISION MAKING, 2000, 20 (03) :332-342
[9]  
Luce B R, 1993, Pharmacoeconomics, V3, P1
[10]   The quality of reporting in published cost-utility analyses, 1976-1997 [J].
Neumann, PJ ;
Stone, PW ;
Chapman, RH ;
Sandberg, EA ;
Bell, CM .
ANNALS OF INTERNAL MEDICINE, 2000, 132 (12) :964-972